A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells

A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells

Chidamide is a novel selective histone deacetylase inhibitor (HDACi) with promising activity in hematological malignancies, but its role in chronic myeloid leukemia (CML) was marginally addressed. In this study, we firstly demonstrated that chidamide alone inhibited CML cells proliferation, induced...

Full description

Bibliographic Details
Main Authors: Bailin He, Qiang Wang, Xiaoli Liu, Ziyuan Lu, Jiaochan Han, Chengyun Pan, Bing Z. Carter, Qifa Liu, Na Xu, Hongsheng Zhou
Format: Article
Language:English
Published: Elsevier 2020-09-01
Series:Biomedicine & Pharmacotherapy
Subjects:
Chronic myeloid leukemia
HDAC inhibitor
Chidamide
β-catenin
Drug resistance
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332220305837

Internet

http://www.sciencedirect.com/science/article/pii/S0753332220305837

Similar Items